35Pharma is a Canada-based, private, clinical-stage biopharmaceutical company headquartered in Montreal, Quebec, with a research hub in Boston, Massachusetts. It designs and develops next-generation protein-based therapeutics — multi-specific Activin x GDF ligand traps engineered against the TGF-beta superfamily — for pulmonary hypertension, heart failure, cardiometabolic disease and obesity. Its lead program, HS235, is a precision-engineered activin signalling inhibitor that has completed Phase I healthy-volunteer studies and is entering proof-of-principle trials in PAH and PH-HFpEF; a second program, HS370, targets heart failure and obesity. 35Pharma publishes no developer program, API, or machine-readable API artifacts of any kind — it is a therapeutics developer, not a software or data provider. On 25 February 2026 the company announced an agreement to be acquired by GSK plc.
35Pharma is profiled on the APIs.io network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Biopharmaceutical, and Drug Development.
Regulatory Posture applies to this provider. Its tags matched the
Health regime, so
Regulatory Posture carries 15 points of the composite.
If this regime is wrong for your business, say so on your
provider repo — the
applicability map is public and we will correct it.
Create-or-Update Ergonomics could not be measured. We hold no machine-readable contract for
this provider to read, so there is nothing to measure a write surface against. Excluded rather than scored zero:
never-measured and measured-empty are different facts. Publishing an OpenAPI is what makes this facet — and
several others — scorable at all.
The six quality facets above are damped to 85 points between them,
because the conditional facet above carries the other
15. That is why each facet's contribution is shown against a damped
maximum: raising a quality facet moves the composite by 85% of its nominal
weight, not 100%. The full arithmetic is at apis.io/rating/.
Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. Every facet and dimension name above is a link: it opens that measurement's own page — what it means, the exact checks that feed it, how the whole catalog distributes on it, and the providers at the top of it. This rating is computed from github.com/api-evangelist/35pharma: open an issue to ask a question, or submit a pull request to add artifacts.
Submit an artifact on GitHub — free →Manage your own listing — the Influence plan, $499/mo →
aid: 35pharma
name: 35Pharma
description: 35Pharma is a Canada-based, private, clinical-stage biopharmaceutical company headquartered in Montreal, Quebec,
with a research hub in Boston, Massachusetts. It designs and develops next-generation protein-based therapeutics — multi-specific
Activin x GDF ligand traps engineered against the TGF-beta superfamily — for pulmonary hypertension, heart failure, cardiometabolic
disease and obesity. Its lead program, HS235, is a precision-engineered activin signalling inhibitor that has completed
Phase I healthy-volunteer studies and is entering proof-of-principle trials in PAH and PH-HFpEF; a second program, HS370,
targets heart failure and obesity. 35Pharma publishes no developer program, API, or machine-readable API artifacts of any
kind — it is a therapeutics developer, not a software or data provider. On 25 February 2026 the company announced an agreement
to be acquired by GSK plc.
url: https://raw.githubusercontent.com/api-evangelist/35pharma/refs/heads/main/apis.yml
image: https://cdn.prod.website-files.com/679106f289641fbcc75092be/6920bf64870d13ff322aff0b_Open%20graph%20logo.jpg
x-type: company
x-source: harvest:secondary-market
x-tier: stub
x-tier-reason: harvest
x-parent-company: gsk
specificationVersion: '0.20'
created: '2026-09-05'
modified: '2026-09-05'
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Biopharmaceutical
- Drug Development
- Clinical Trials
- Life Sciences
- Protein Engineering
- Healthcare
apis: []
maintainers:
- FN: Kin Lane
email: kin@apievangelist.com
- FN: APIs.json
email: info@apis.io
common:
- type: Website
url: https://www.35pharma.com/
- type: PressReleases
url: https://www.35pharma.com/news
- type: Careers
url: https://www.35pharma.com/careers
- type: PrivacyPolicy
url: https://cdn.prod.website-files.com/679106f289641fbcc75092be/690117401d052d425a9a6c62_35Pharma_PrivacyPolicy_EN_FR.pdf
- type: ParentCompany
url: https://www.gsk.com
- type: DomainSecurity
url: security/35pharma-domain-security.yml
x-enrichment:
date: '2026-09-05'
status: minimal
artifacts_added: 2
pass: local-v3
x-coverage:
state: none
reason: not-a-software-company
detail: 35Pharma is a clinical-stage biopharmaceutical company developing Activin x GDF ligand-trap biologics (lead asset
HS235); its entire public site is seven marketing pages — technology, pipeline, about, careers, news, publications — with
no developer section, no API, and no machine-readable artifact on any probed path.
evidence:
- url: https://www.35pharma.com/sitemap.xml
status: 200
- url: https://www.35pharma.com/openapi.json
status: 404
- url: https://www.35pharma.com/llms.txt
status: 404
- url: https://www.35pharma.com/.well-known/agent-card.json
status: 404
- url: https://www.35pharma.com/apis.json
status: 404
checked: '2026-09-05'
Discovery needs no key. Ratings and market analysis are Pro.
Get an API key
Free tier, no form to fill in. Signing in shares your email address with us — we
store it to create your key and to recognise you if you sign in with another
provider. See our Privacy Policy and
Terms.